Gender and AF: Differences and Disparities

Naga Venkata Pothineni, MD, and Srikanth Vallurupalli, MD

Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR

Abstract
AF is the most common clinical arrhythmia encountered. A wealth of evidence has improved our ability to diagnose and effectively treat AF. An intriguing aspect of this common disease – gender-based differences – is well recognized, but poorly understood. In this brief review, we will explore the accumulating evidence suggesting a gender-based disparity in the prevalence, pathogenesis and management of AF.

Keywords
AF, stroke, gender differences, health disparities, anticoagulants

Disclosure: The authors have no conflicts of interest to declare.

Received: December 21, 2017 Accepted: January 12, 2018 Citation: US Cardiology Review 2018;12(2):103–6. DOI: https://doi.org/10.15420/usc.2017:39:1

Correspondence: Naga Venkata Pothineni, 4301 W Markham Street, #532, Little Rock, AR 72205, USA. E: nvpothineni@uams.edu

AF is the most common clinically relevant supraventricular arrhythmia. AF is a leading risk factor for stroke and accounts for about one-third of all ischemic cerebrovascular events. The last two decades have witnessed a paradigm shift in the management of AF with the development of catheter ablation and improvements in anticoagulant therapies. In this review, we discuss gender-related differences and disparities in the pathophysiology, clinical presentation, and management of AF.

Gender Differences in the Pathophysiology of AF
Men are more susceptible to the development of AF. However, since women live longer than men, the cumulative lifetime risk of AF is similar in men and women, at about 30 %. On average, women develop AF 10 years later than men. Differences in atrial effective refractory period (ERP) in response to rapid atrial pacing have been reported in men and women. The degree of shortening of atrial ERP was significantly less in premenopausal women compared with menstrual women and age-matched men, suggesting the protective role of estrogen. In addition, non-pulmonary vein triggers are more frequent in women with AF compared with men. More recent evidence points to genetic disparities in ion channel expression between men and women. Ambrosi et al. investigated the mRNA expression of 89 ion channel subunits, calcium handling proteins, and transcription factors important in cardiac conduction and arrhythmogenesis. Gender-specific analysis showed lower expression levels in transcripts encoding for K\textsubscript{v}4.3, K\textsubscript{ChIP}2, K\textsubscript{v}1.5, and K\textsubscript{ir}3.1 in the failing female left atrium compared with the male left atrium. Gender differences in autonomic control of the cardiovascular system have been described as well. Sympathetic-mediated responses predominate in men, while women have higher degrees of parasympathetic activation, which has been associated with an increased propensity of AF due to extensive vagal innervation of the atrial muscle sleeves extending into the pulmonary veins.

Morphologically, significant gender-based differences in AF-related atrial remodeling have been observed. Fibrotic remodeling of the left atrium leads to electrical dissociation of atrial cells that contributes to higher incidence and recurrence rates of AF. Li et al. analyzed tissue samples from men and women with long-standing, persistent AF and showed that women have a significantly higher degree of fibrotic remodeling compared with men. This morphological difference was driven by differential expression of fibrosis-related genes and proteins, such as transforming growth factor-beta, which were upregulated in women with persistent AF. Cochet et al. reported that female gender was independently associated with delayed gadolinium enhancement in patients with AF, as well as in patients with no AF or structural heart disease. In a subanalysis of the AF Follow-up Investigation of Rhythm Management (AFFIRM) trial, female gender was significantly associated with higher rates of left atrial remodeling and adverse cardiovascular endpoints.

Gender modulates how various risk factors contribute to AF. Obesity appears to impart a higher risk of AF in men compared with women (hazard ratio [HR] per standard deviation increase 1.18; 95 % CI [1.12–1.23] in women versus 1.31; 95 % CI [1.25–1.38] in men; P\textsubscript{interaction}<0.001). Women with AF have a lower prevalence of coronary disease and sleep apnea compared with men. However, hypertension and heart failure with preserved ejection fraction are more prevalent in women with AF, likely reflecting the later age of onset.

Gender Differences in the Clinical Presentation of AF
Substantial differences in clinical symptomatology of AF exist between men and women. In the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF) registry, women with AF experienced more symptoms and worse quality of life in comparison with men. Similarly, in the Euro Observational Research Program on AF (EORP-AF) pilot survey women...
Gender Differences in AF Management

Rate Control
Gender bias is apparent in the choice of medications for rate control of AF. In the ORBIT-AF registry, women were less likely to receive beta-blocker therapy (62.0% versus 65.5%) and were more likely to receive digoxin (24.6% versus 22.6%). In the EORP-AF registry, use of digoxin as a rate-control agent was significantly more common in women (25% versus 19.8%), while there was no difference in prescription rates of beta-blockers. In the Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in AF (ROCKET-AF) trial, digoxin was used in 42% of female participants compared with 38% of males, and digoxin use was associated with increased all-cause mortality, vascular death and sudden death. Other studies have also revealed an association between digoxin and higher rates of cardiac death. In this context, the consistently higher rates of use of digoxin as a rate-control agent is worrisome. Whether this reflects poor tolerability to commonly used rate-control medications is unknown.

Gender-specific differences also appear to exist in the use of non-pharmacological rate-control measures. In the ORBIT-AF registry, women had significantly higher rates of atrioventricular nodal ablation and pacemaker implantation (adjusted HR 1.97; 95% CI [1.30–2.97]) compared with men over a median follow-up of 2.3 years.

Rhythm Control
Gender differences in rates of prescription of anti-arrhythmic medications for AF have been debated. In the EORP-AF survey, rhythm control was less commonly utilized in women, despite a higher rate of symptomatic AF and lower quality of life. Rates of electrical cardioversion were 18.9% in women compared to 25.5% in men. In the PREFER in AF observational cohort, women were more likely to receive pharmacological cardioversion while men had higher rates of electrical cardioversion. However, in the ORBIT-AF registry, there was no difference in rates of anti-arrhythmic medication use in women compared with men. In a nationwide analysis of all in-patient cardioversions in the US, we have previously reported that in-hospital rates of electrical cardioversion were significantly higher in men compared with women (58.4% versus 48.6%). Rates of AF recurrence following cardioversion have also been reported to be higher in women.

In this context, it is important to understand that women appear to have a higher risk of side-effects with rhythm-control strategies. Women with AF on Class IA and III anti-arrhythmic medications have higher rates of torsades de pointes and bradyarrhythmias requiring a pacemaker. In the Fibrillation Registry Assessing Costs, Therapies, Adverse Events, and Lifestyle (FRACTAL) registry, Essesbag et al. have reported that female gender was an independent risk factor that determines the need for a pacemaker in patients taking amiodarone for AF. Catheter Ablation
Catheter ablation has emerged as an important therapeutic strategy in the management of AF. Significant gender disparities in utilization of catheter ablation, in which women are referred later and less frequently for catheter ablation of AF compared with men, have been identified. Women referred for ablation are older, and have larger indexed left atrial dimensions. In a nationwide analysis of AF ablation procedures, women were 17% less likely to undergo catheter ablation compared with men. Another analysis of AF care strategies in Medicare beneficiaries demonstrated significantly lower referral rates for catheter ablation in women (HR 0.65; 95% CI [0.63–0.68]), even after adjusting for multiple confounding variables. There is similar under-representation of women in randomized trial data of AF ablation (Table 1). A meta-analysis of all AF ablation clinical trials reported that women constitute only one-fifth of the study population.

In addition to disparities in utilization, gender-based differences in efficacy and safety of AF ablation also exist. Women suffered from a higher risk of complications after AF ablation in multiple studies. Patel et al. reported that women undergoing catheter ablation more often had persistent AF, a higher proportion of non-pulmonary vein triggers, lower ablation success rates, and significantly higher complication rates, the latter driven primarily by vascular complications. In a nationwide analysis of AF ablation complications, overall, women had higher in-hospital complication rates than men (7.51% versus 5.49%; p<0.001). A more recent study reported that women undergoing AF ablation had a higher risk of vascular-related complications, hemorrhage, and perforation or tamponade, and that overall, women had an increased risk of all-cause hospitalization compared with men (9.4% versus 8.6%; p<0.001). Various patient-related factors could explain the higher rates of vascular and hemorrhagic complications in women. Female patients tend to have smaller vessel calibers compared with men, which may increase the risk of vascular injury. In AF ablation studies, women have been shown to have higher activated partial thromboplastin times compared with men, even when lower doses of heparin are administered. However, although these are interesting hypotheses, the underlying mechanism leading to higher complication rates in women is yet to be deciphered.

Gender Differences in Stroke Risk
AF is a well-recognized risk factor for stroke. In a retrospective Swedish AF cohort study of 100,802 patients with AF, female gender was an independent risk factor for stroke (HR 1.18; 95% CI [1.12–1.24]), even after adjusting for multiple confounding variables. As described earlier, women with AF tend to have larger left atrial volumes and reduced atrial contractility compared with men, which can increase the risk of atrial thrombi. Elderly postmenopausal women also have higher rates of diastolic dysfunction and elevated systolic blood pressure compared with men, which can lead to accelerated cardiovascular remodeling and endothelial dysfunction that translates into a higher risk of stroke.
Gender and AF

Efficacy of Anticoagulants

For many decades, warfarin was the choice of anticoagulant for stroke prophylaxis in AF. Direct-acting oral anticoagulants (DOACs) are now available and have been shown to be non-inferior in stroke prevention. Analysis of trial data demonstrates some gender-specific differences in efficacy and risk of bleeding with the use of these medications.

Warfarin

A meta-analysis of five randomized controlled trials of patients with AF reported that warfarin reduces the risk of ischemic stroke by 84% (95% CI [55–95%]) in women compared with 60% (95% CI [35–76%]) in men. However, more recent evidence indicates that women have a higher residual stroke risk compared with men receiving oral anticoagulation. In a post hoc analysis of the AFFIRM trial, Sullivan et al. reported that women were at greater risk of ischemic stroke than men despite similar anticoagulation patterns. The difference in ischemic stroke risk was primarily related to a higher proportion of women being outside the therapeutic range for warfarin. Time in therapeutic range is recognized as a major factor determining stroke risk in AF patients on warfarin. A recent meta-analysis also reported similar findings, showing that female patients with AF on warfarin had a significantly higher residual risk of stroke and systemic thromboembolism than men (OR 1.28, 95% CI [1.11–1.47]).

Direct-acting Oral Anticoagulants

Gender-based differences in stroke risk are less obvious in trials of DOACs. A meta-analysis of 71,683 participants included in the ROCKET-AF, Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY), Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE), and Effective Anticoagulation with Factor Xa Next Generation in AF – Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trials showed no gender-based differences in stroke or bleeding risk among patients assigned to DOACs.

In summary, although prior trials of stroke prevention in AF revealed a higher rate of ischemic stroke in women with AF on warfarin, DOACs appear to not suffer from this gender-based difference in efficacy (Table 2).

Conclusion

Multiple studies have shown major gender-based differences in the clinical profile and management of AF. Whether these are related to differences in biology or represent treatment disparities is unknown. This area of cardiac electrophysiology deserves further study.

### Table 1: Representation of Women in Major Randomized Clinical Trials of AF Ablation

| Authors       | Trial       | Year | Ablations | Female Participants (n) |
|---------------|-------------|------|-----------|-------------------------|
| Stabile et al. | CACAF       | 2003 | 68        | 31 (45.5%)              |
| Wazni et al.   | RAAFT       | 2005 | 33        | Not reported            |
| Oral et al.    |             | 2006 | 77        | 10 (12.9%)              |
| Papone et al.  | APAF        | 2006 | 99        | 30 (30.3%)              |
| Jais et al.    | A4          | 2008 | 53        | 8 (15.1%)               |
| Forleo et al.  |             | 2009 | 35        | 14 (42.9%)              |
| Wilber et al.  | Thermocool AF | 2010 | 106       | 33 (31.1%)              |
| Nielsen et al. | MANTRA PAF  | 2012 | 146       | 46 (32%)                |
| Packer et al.  | STOP AF     | 2013 | 163       | 38 (22.3%)              |

### Table 2: Gender Differences in Stroke Risk in Anticoagulation Trials of AF

| Author       | Study       | Year | n   | Men (n) | Women (n) | Anticoagulant | Stroke Rate (%) |
|--------------|-------------|------|-----|---------|------------|---------------|-----------------|
| Hart et al.  | SPAF        | 1999 | 1,853 | 1,339 (72.3%) | 514 (27.7%) | Warfarin | 2.1 | 4.4 |
| Fang et al.  | ATRIA       | 2005 | 13,559 | 7,764 (57.3%) | 5,795 (42.7%) | Warfarin | 1.8 | 3.5 |
| Rienstra et al. | RACE     | 2005 | 522  | 330 (63.2%) | 192 (36.8%) | Warfarin | 6.7 | 6.8 |
| Gomberg et al. | SPORTIF   | 2006 | 7,329 | 5,072 (69.2%) | 2,257 (30.8%) | Warfarin | 1.4 | 2.1 |
| Connolly et al. | RELY      | 2009 | 12,091 | 7,705 (63.7%) | 4,386 (36.3%) | Dabigatran | 1.4 | 1.9 |
| Connolly et al. | AVERROES  | 2011 | 2,808 | 1,660 (59.1%) | 1,148 (40.9%) | Apixaban | 1.4 | 1.9 |
| Patel et al. | ROCKET AF   | 2011 | 7,131 | 4,300 (60.3%) | 2,831 (39.7%) | Rivaroxaban | Not reported | Not reported |
| Granger et al. | ARISTOTLE | 2011 | 9,120 | 5,886 (64.5%) | 3,234 (35.5%) | Apixaban | 1.2 | 1.4 |
| Guijilano et al. | ENGAGE AF-TIMI 48 | 2015 | 21,105 | 13,065 (61.9%) | 8,040 (38.1%) | Edoxaban | 1.16 | 1.21 |

ARFFIRM = Atrial Fibrillation Follow-up Investigation of Rhythm Management; ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF; ATRIA = Anticoagulation and Risk Factors in AF; AVERROES = Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in AF Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; ENGAGE AF-TIMI 48 = Effective Anticoagulation with Factor Xa Next Generation in AF – Thrombolysis in Myocardial Infarction 48; RELY = Rate Control versus Electrical Cardioversion for Persistent AF; RE-LY = Randomized Evaluation of Long-term Anticoagulation Therapy; SPAF = Stroke Prevention in AF; SPORTIF = Stroke Prevention Using Oral Thrombin Inhibitor in AF.
1. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Circ Res 1979; 45:289-7. https://doi.org/10.1161/01.RES.45.3.289.

2. Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and cardiovascular risk factors. Am J Cardiol 2013; 112:1687-96. https://doi.org/10.1016/j.amjcard.2013.06.038; PMID: 23864847.

3. Bidoggia H, Maciel JP, Capalozza N, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: possible autonomic control of the cardiovascular system. Car Physiol 2011; 22:2829-34. https://doi.org/10.1111/j.1749-0833.2011.12661.x; PMID: 22749316.

4. Wolbrette D, Naccarelli G, Curtis A, et al. Gender differences in stroke after cardioversion of atrial fibrillation. Stroke 2016; 47:2498-505. https://doi.org/10.1161/STROKEAHA.115.010422; PMID: 27473024.

5. Pirovietti M, Rapaport B, Bazili S, et al. Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation. J Int Med Res 2015; 43:262-71. https://doi.org/10.1177/0300060515572756; PMID: 25933770.

6. Schroth PG, Pesenti O, Onda GM, et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. J Am Coll Cardiol 2016; 67:2124-31. https://doi.org/10.1016/j.jacc.2016.03.075; PMID: 27282467.

7. Emdin CA, Wang C, Hislop A, et al. Atrial fibrillation as risk factor for future ischemic stroke and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2015; 351:h5113. https://doi.org/10.1136/bmj.h5113; PMID: 26228467.

8. Washam JL, Stivers SR, Lokhnygna Y, et al. Diguine use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). J Am Coll Cardiol 2015; 65:2563-70. https://doi.org/10.1016/j.jacc.2015.02.046; PMID: 25799502.

9. Turkeltaub MP, Santangelo P, Winklemyer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREND-AF study. Am J Cardiol 2014; 114:666-8. https://doi.org/10.1016/j.amjcard.2013.03.060; PMID: 25125296.

10. Rechcigl YM, Shan NN, Pothineni NV, Padayil H. Utilization and predictors of electrical cardioversion in patients hospitalized for atrial fibrillation. Cardiovasc Interv Ther 2016; 31:899-600. https://doi.org/10.1007/s12960-016-0286-6; PMID: 26966808.

11. Gurevitz DO, Varadachari CJ, Ammassi AM, et al. The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion. Am Heart J 2006; 152:155-9. https://doi.org/10.1016/j.amjcard.2006.04.030; PMID: 16684847.

12. Esmaili V, Reynolds MR, Haq T, et al. Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med 2007; 167:1648-53. https://doi.org/10.1001/archinte.167.11.1648; PMID: 17698688.

13. Takigawa M, Kuwashita T, Takashashi A, et al. Differences in catheter ablation of paroxysmal atrial fibrillation between males and females. J Int Med Res 2013; 41:1984-91. https://doi.org/10.1177/0300060513495970; PMID: 23782910.

14. Patel N, Deshmukh A, Thukar B, et al. Gender, race, and health insurance status in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2016; 117:111-6. https://doi.org/10.1016/j.amjcard.2016.01.040; PMID: 26894194.

15. Bhave PD, Lu X, Gironda S, et al. Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm 2016; 13:4566-72. https://doi.org/10.1016/j.hrthm.2015.10.031; PMID: 25814148.

16. Stable JG, Bertaglia E, Senatore G, et al. Feasibility of pulmonary vein ostia radiofrequency ablation in patients with atrial fibrillation: a multicenter study (CACAF pilot study). Pacing Clin Electrophysiol 2016; 39:2634-40. https://doi.org/10.1111/pace.13295; PMID: 15929285.

17. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary vein ablation for chronic atrial fibrillation. Eur Heart J 2016; 37:5941-4. https://doi.org/10.1093/eurheartj/ehw359; PMID: 16570577.

18. Pappone C, Auzello S, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2009; 292:2363-40. https://doi.org/10.1001/jama.2009.2136; PMID: 19592825.

19. The AFFIRM Trial. J Am Coll Cardiol 2009; 53:2498-505. https://doi.org/10.1016/j.jacc.2008.05.037; PMID: 19066207.

20. The Framingham study. Am J Cardiol 1994; 73:12–6. https://doi.org/10.1016/0002-9149(94)90253-5; PMID: 8307466.

21. Gibbons RJ, Balady GJ, Beasley JD, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable ischemic heart disease—summary report. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Ischemic Heart Disease). J Am Coll Cardiol 2002; 40:1387-425. https://doi.org/10.1016/S0735-1097(02)02144-7; PMID: 12186251.

22. The AFFIRM Trial. J Am Coll Cardiol 2009; 53:2498-505. https://doi.org/10.1016/j.jacc.2008.05.037; PMID: 19066207.

23. Gibbons RJ, Balady GJ, Beasley JD, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable ischemic heart disease—summary report. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Ischemic Heart Disease). J Am Coll Cardiol 2002; 40:1387-425. https://doi.org/10.1016/S0735-1097(02)02144-7; PMID: 12186251.

24. Gibbons RJ, Balady GJ, Beasley JD, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable ischemic heart disease—summary report. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Ischemic Heart Disease). J Am Coll Cardiol 2002; 40:1387-425. https://doi.org/10.1016/S0735-1097(02)02144-7; PMID: 12186251.

25. Gibbons RJ, Balady GJ, Beasley JD, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable ischemic heart disease—summary report. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Ischemic Heart Disease). J Am Coll Cardiol 2002; 40:1387-425. https://doi.org/10.1016/S0735-1097(02)02144-7; PMID: 12186251.